AVITA Medical Entered Into An Exclusive Multi-Year Marketing, Sales And Distribution Rights To A Unique Collagen-Based Dermal Matrix, Which Will Be Manufactured By Regenity Biosciences
Portfolio Pulse from Benzinga Newsdesk
AVITA Medical (NASDAQ: RCEL) has entered into an exclusive multi-year agreement with Regenity Biosciences for the marketing, sales, and distribution of a unique collagen-based dermal matrix, pending FDA 510(k) clearance.
July 31, 2024 | 9:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
AVITA Medical has secured exclusive multi-year marketing, sales, and distribution rights for a unique collagen-based dermal matrix from Regenity Biosciences, pending FDA 510(k) clearance.
The exclusive agreement with Regenity Biosciences positions AVITA Medical to expand its product offerings in the regenerative medicine market. The pending FDA 510(k) clearance is a critical step, but the announcement is likely to positively impact investor sentiment in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100